BioCryst Pharmaceuticals, Inc.
BCRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, BioCryst Pharmaceuticals, Inc. (BCRX) is listed under Drug Manufacturers - Specialty & Generic. Valued at $2.36B, BCRX is a mid-cap name in its sector. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Market Cap
$2.36B
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
10.04
EPS (TTM)
$-1.81
EPS (Fwd)
$0.93
ROE
—
ROA
42.6%
Cash
$238.4M
Total Debt
$858.1M
Free CF
$264.4M
52W Change
7.9%
Annual Financials
Cash vs Debt
BioCryst Pharmaceuticals, Inc. carries $858.1M in total debt against $238.4M in cash reserves — debt is roughly 3.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $264.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on assets of 42.6% further supports the picture of efficient asset utilization. Revenue has grown from $270.8M (2022) to $874.8M (2025), reflecting a 223% increase over the period.
With a beta below 0.7, BioCryst Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioCryst Pharmaceuticals, Inc. and its sector.